Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort

Raphael Micheroli; Christoph Tellenbach; Almut Scherer; Kristina Bürki; Karin Niederman; Michael J Nissen; Pascal Zufferey; Pascale Exer; Burkhard Möller; Diego Kyburz; Adrian Ciurea

doi:10.1136/annrheumdis-2019-215934

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Archive
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Citation Tools

Spondyloarthritis

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Micheroli R, Tellenbach C, Scherer A, et al

Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort

Annals of the Rheumatic Diseases 2020;79:1203-1209.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password